PMID

Data

Article Title

Organization

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

Shandong University

Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.

Icahn School of Medicine At Mount Sinai

Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor.

University of Toronto

Selective inhibitors of protein methyltransferases.

Icahn School of Medicine At Mount Sinai

Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.

University of North Carolina At Chapel Hill

Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Entremed

Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors.

University of North Carolina At Chapel Hill

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

TBA

Synthesis and evaluation of carbocyanine dyes as PRMT inhibitors and imaging agents.

Georgia State University

Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1).

Bristol-Myers Squibb Pharmaceutical Research and Development

Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.

University of North Carolina At Chapel Hill

Discovery and mechanistic study of a class of protein arginine methylation inhibitors.

Georgia State University

Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.

University of North Carolina At Chapel Hill

Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies.

Bristol-Myers Squibb Pharmaceutical Research and Development

Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).

Bristol-Myers Squibb Pharmaceutical Research and Development

Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.

Institut De G£N£Tique Et De Biologie Mol£Culaire Et Cellulaire

A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.

Icahn School of Medicine At Mount Sinai

Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

University of Michigan Medical School

Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases.

University of Georgia

New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.

University College London

Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.

University of Toronto

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.

Shanghai Institute of Materia Medica

Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia.

Chinese Academy of Sciences

Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.

Icahn School of Medicine At Mount Sinai

Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3).

Icahn School of Medicine At Mount Sinai

Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation.

Zhejiang Sci-Tech University